HALO · Halozyme Therapeutics, Inc.
Market Cap
$12.37B
Shares
113.50M
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Revenue
$1.4B
+37.6%
FY2025
Net Income
$316.89M
-28.6%
FY2025
Gross Margin
83.62%
-0.7pp
FY2025
Operating Margin
33.58%
-20.7pp
FY2025
Diluted EPS
$2.56
-25.4%
FY2025
Operating Cash Flow
$651.56M
+36%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $1.66B | $1.4B | $1.02B | $829.25M | $660.12M | $443.31M | $267.59M | $195.99M | $151.86M | $316.61M | $146.69M | $135.06M | $75.33M | $54.8M | $42.33M | $56.09M | $13.62M | $13.67M | |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | $59.03K | $63.53K | $49.02K | $100.75K | |
| $292.42M | $228.77M | $159.42M | $192.36M | $139.3M | $81.41M | $43.37M | $45.55M | $10.14M | $31.15M | $33.21M | $29.25M | $22.73M | $6.25M | $1.09M | $257.83K | $985.28K | $311.89K | |
| $1.37B | $1.17B | $855.91M | $636.89M | $520.81M | $361.9M | $224.23M | $150.45M | $141.73M | $285.46M | $113.49M | $105.81M | $52.6M | $48.55M | $41.23M | $55.83M | $12.64M | $13.36M | |
| — | 83.62% | 84.3% | 76.8% | 78.9% | 81.64% | 83.79% | 76.76% | 93.33% | 90.16% | 77.36% | 78.35% | 69.83% | 88.6% | 97.42% | 99.54% | 92.77% | 97.72% | |
| $102.37M | $81.49M | $79.05M | $76.36M | $66.61M | $35.67M | $34.24M | $140.8M | $150.25M | $150.64M | $150.84M | $93.24M | $79.7M | $96.64M | $70.04M | $57.56M | $51.77M | $56.61M | |
| $238M | $207.09M | $154.34M | $149.18M | $143.53M | $50.32M | $45.74M | $77.25M | $60.8M | $53.82M | $45.85M | $40.03M | $35.94M | $32.35M | $24.81M | $18.1M | $15.12M | $15.2M | |
| $100.16M | $76.66M | $71.05M | $73.77M | $43.15M | $0 | $0 | — | — | — | — | — | — | — | — | — | — | — | |
| $14.72M | $11.39M | $10.26M | $11.08M | $6.49M | $3M | $3.28M | $4.07M | $2.39M | $2.16M | $2.41M | $1.68M | $1.76M | $1.23M | $1.08M | $1.1M | $1.51M | $1.44M | |
| $1.07B | $927.61M | $463.85M | $491.68M | $392.59M | $167.41M | $123.34M | $263.6M | $221.19M | $235.61M | $229.9M | $162.51M | $138.37M | $135.23M | $95.95M | $75.93M | $67.88M | $72.13M | |
| $597.2M | $469.01M | $551.48M | $337.57M | $267.53M | $275.9M | $144.26M | -$67.61M | -$69.33M | $81M | -$83.21M | -$27.45M | -$63.04M | -$80.43M | -$53.63M | -$19.84M | -$54.26M | -$58.46M | |
| — | 33.58% | 54.32% | 40.71% | 40.53% | 62.24% | 53.91% | -34.5% | -45.65% | 25.58% | -56.72% | -20.33% | -83.68% | -146.78% | -126.7% | -35.37% | -398.25% | -427.6% | |
| $611.92M | $480.4M | $561.74M | $348.66M | $274.02M | $278.9M | $147.54M | -$63.54M | -$66.94M | $83.16M | -$80.8M | -$25.78M | -$61.27M | -$79.21M | -$52.55M | -$18.74M | -$52.75M | -$57.01M | |
| $20.3M | $18.13M | $18.1M | $18.76M | $16.95M | $7.53M | $20.38M | $11.63M | $18.04M | $21.98M | $19.98M | $5.2M | $5.58M | $3.27M | $0 | $0 | — | — | |
| $11.92M | $21.47M | $23.75M | $16.32M | $1.05M | $1.1M | $5.43M | $6.99M | $7.58M | $2.59M | $1.33M | $422K | — | — | $73.44K | $69.09K | $1.02M | $97.74K | |
| $583.34M | $466.88M | $557.13M | $348.33M | $248.92M | $248.52M | $129.3M | -$72.25M | -$79.79M | $61.61M | -$101.86M | -$32.23M | -$68.38M | — | — | — | — | — | |
| $169.74M | $149.99M | $113.04M | $66.74M | $46.79M | -$154.19M | $217K | -$11K | $537K | -$1.36M | $1.16M | $0 | $0 | — | — | — | — | — | |
| $413.6M | $316.89M | $444.09M | $281.59M | $202.13M | $402.71M | $129.09M | -$72.24M | -$80.33M | $62.97M | -$103.02M | -$32.23M | -$68.38M | -$83.48M | -$53.55M | -$19.77M | -$53.24M | -$58.36M | |
| — | 22.69% | 43.74% | 33.96% | 30.62% | 90.84% | 48.24% | -36.86% | -52.9% | 19.89% | -70.23% | -23.86% | -90.76% | -152.34% | -126.53% | -35.25% | -390.79% | -426.88% | |
| $434.17M | $294.97M | $457.2M | $273.24M | $201.83M | $402.07M | $128.87M | -$71.72M | -$80.16M | $62.53M | -$102.93M | -$32.29M | -$68.43M | -$83.46M | -$53.55M | -$19.77M | -$53.24M | — | |
| USD/shares | $3.55 | $2.64 | $3.50 | $2.13 | $1.48 | $2.86 | $0.95 | -$0.50 | -$0.56 | $0.46 | -$0.81 | -$0.25 | — | — | — | — | — | — |
| USD/shares | $3.42 | $2.56 | $3.43 | $2.10 | $1.44 | $2.74 | $0.91 | -$0.50 | -$0.56 | $0.45 | -$0.81 | -$0.25 | — | — | — | — | — | — |
| shares | — | 119.84M | 126.83M | 131.93M | 136.84M | 140.65M | 136.21M | 144.33M | 143.6M | 136.42M | 127.96M | 126.7M | 122.69M | 112.81M | 111.08M | 102.57M | — | — |
| shares | — | 123.9M | 129.42M | 134.2M | 140.61M | 146.8M | 141.46M | 144.33M | 143.6M | 139.07M | 127.96M | 126.7M | 122.69M | 112.81M | 111.08M | 102.57M | — | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2017–FY2025: $1.89B in buybacks.
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Coverage backlog: 44 eligible filings and 0 covenant artifacts have no current-version terminal extraction result. This includes untouched sources and sources on the retry ladder.
No terminal debt extraction result is available yet; this is not evidence that the company has no debt.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
8.64×
Peer median 10.05×
EV/EBIT
24.08×
Peer median 39.85×
P/E (TTM)
31.87×
Peer median 20.80×
Peer medians compare against the 131 similar-size Biotechnology companies (of 515 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Royalty | $867,840,000 | $570,991,000 | $447,865,000 | $360,475,000 | $203,900,000 | $88,596,000 | $69,899,000 | $78,981,000 |
| Product | $376,444,000 | $303,492,000 | $300,854,000 | $191,030,000 | $104,224,000 | $55,987,000 | $66,048,000 | $28,234,000 |
| Proprietary Products Sales | $194,608,000 | $166,620,000 | $130,834,000 | $72,849,000 | $23,264,000 | $17,031,000 | — | — |
| Collaborative Agreements | $152,327,000 | $140,841,000 | $80,534,000 | $108,611,000 | $135,186,000 | $123,011,000 | $60,045,000 | $44,647,000 |
| Bulk rHuPH20 | $133,023,000 | $86,334,000 | $115,442,000 | $82,084,000 | $80,960,000 | $38,956,000 | $49,053,000 | $12,729,000 |
| Sales-Based Milestone | $70,000,000 | $30,000,000 | $0 | $10,000,000 | $50,000,000 | $15,000,000 | $0 | $0 |
| Device Partnered Products | $48,813,000 | $50,538,000 | $54,578,000 | $36,097,000 | $0 | $0 | — | — |
| Event Based Development And Regulatory Milestone And Other Fees | $47,000,000 | $72,500,000 | $69,000,000 | $59,000,000 | $42,000,000 | — | — | — |
| Upfront Fees | $18,471,000 | $27,000,000 | $2,000,000 | $30,000,000 | $42,000,000 | $37,264,000 | $53,000,000 | $26,336,000 |
| Device Licensing and Development | $16,856,000 | $11,341,000 | $9,534,000 | $9,611,000 | — | — | — | — |
| Development Fees | — | — | — | $59,000,000 | $42,000,000 | $69,500,000 | $5,500,000 | $16,000,000 |
| ENHANZE Drug Product Member Domain | — | — | — | — | — | $719,000 | $768,000 | $460,000 |
| Hylenex Recombinant | — | — | — | — | $23,263,000 | $17,031,000 | $16,995,000 | $15,045,000 |
| Research and Development Services | — | — | $9,534,000 | $9,611,000 | $1,186,000 | $1,247,000 | $1,545,000 | $2,311,000 |
Key facts
CIK
1159036
CUSIP
40637H109
13F (30d)
404 filings
386 filers
Visit website
Investor relations